Market Overview

UPDATE: Jefferies Raises PT on Infinity Pharmaceuticals on IPI-145 Sales Potential

Related INFI
Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
New Biotech Pair Trade: Infinity Pharma Over ImmunoGen
Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day (Zacks)

In a report published Wednesday, Jefferies reiterated its Hold rating on Infinity Pharmaceuticals (NASDAQ: INFI), and raised its price target from $21.00 to $41.00.

Jefferies noted, “Wider 4Q12 loss of ~$47M (vs. our loss estimate of ~$29M); cash of $327M at YE12 sufficient into ~2015. With expanding cohorts in Ph1/2a, timing for Ph3 start is likely in ~2014. INFI's rising valuation implies IPI-145 sales potential at >~$3B; however, given evolving competitive field with several promising products well ahead of IPI-145, speedy, comprehensive development strategy is key to realizing its commercial potential.”

Infinity Pharmaceuticals closed on Tuesday at $45.14.

Latest Ratings for INFI

Sep 2015Morgan StanleyUpgradesEqual-weightOverweight
May 2015Deutsche BankInitiates Coverage onBuy
Jan 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters